A China-based firm invests from a US$700M healthcare fund with an investment strategy focused on global growth opportunities. The company’s US offices have a US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

A venture capital firm with offices throughout the USA and Asia has recently closed its fifth fund of over $220M and is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in China and Southeast Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A London-based fund interested in advanced therapeutics invests in both private and public companies throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead. The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm prefers investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharmaceutical company based in Russia, with additional offices worldwide is actively seeking partnering and in-licensing opportunities across all developmental stages globally.

The firm’s partnering interests are primarily in the hospital care areas. The firm is looking for collaboration in oncology (in therapeutics and diagnostics), autoimmune/inflammatory diseases, novel antibacterial products and diagnostics (particularly in application to Gram-negative organisms), anti-viral, anti-fungal therapeutics, diagnostics for acute hospital care, rare/orphan disease areas, and cell therapies. The firm is seeking to in-license early-stage assets from pre-clinical to Phase I. However, with rare and orphan disease therapeutics, the company will prefer later-stage clinical assets.

The firm seeks to work with companies developing innovative therapeutics and management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the US Midwest is focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accoutability (these do not have to sell D2C, most of their companies do not). The firm manages over $100M in capital with initial investments of $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed stage to Series B, with a focus just at or before the A round.

The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.

The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Canada provides equity capital to portfolio companies and is very flexible in the size of investments it makes, placing a high emphasis on innovation of potential portfolio companies. The firm is currently investing in Canadian companies only, with no set limit on the amount of funds or number of investments.

The firm is looking to invest primarily in innovative green technology as well as biotech therapeutics and medical technology, and is also open to looking at companies in diagnostics and healthcare IT. The firm will consider products of any stage of development, from pre-clinical to phase III as long as the company’s product displays high potential to positively impact the environment or healthcare. In addition, the firm is agnostic to indication and will look at anything that fits in the environment or healthcare sectors.

The firm has taken a board seat in its portfolio companies before, but this is not required by the firm. The companies do not need to have an experienced management team, as innovation is the most important factor that the firm expects from companies. The firm prefers to act as the lead investor, but is open to co-investing with other firms that share the firm’s interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in California invests in primarily early-stage (seed, Series A) companies with truly innovative technologies with a typical investment size of $2-5M per company and can invest as low as $500K. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is seeking innovative technology that is outside traditional biotech. The company is agnostic across life science sectors, including therapeutics, devices, and tools, but will not look at Healthcare IT or digital health technologies. They are interested in therapeutics targeting novel first-in-class targets, and not in biosimilars or repurposed drugs. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com